Mila – Quebec AI Institute, the world’s largest academic deep learning (DL) research center announced today its partnership with iMediSync whose mission is to innovate mental health by using a data-driven approach and artificial intelligence (AI) technologies. iMediSync is a Korean-based international digital mental healthcare company specializing in brainwave-centered diagnostics for early prediction and screening of various brain diseases and precision digital therapeutics using near-infrared light emitting diodes (NIR-LED). The collaboration between Mila and iMediSync signifies a significant leap forward in AI-driven mental healthcare, highlighting their commitment to solve the most serious social problems threatening our sustainability.

“We are thrilled to partner with Mila, a world-leading institution in AI research. This collaboration allows us to harness the power of AI to develop cutting-edge solutions that will transform the diagnosis and treatment of brain dysfunctions,” said Dr. Seung Wan Kang CEO of iMediSync. “Together, we will propel the field forward, leveraging our expertise and Mila’s research prowess to make a tangible difference in patients’ lives.”

The collaboration between Mila and iMediSync is to propel the intersection of AI and mental healthcare, fostering the creation of groundbreaking solutions for detecting and addressing brain dysfunctions. This partnership marks a significant stride forward for the field, paving the way for novel developments in diagnosis and treatment.

“AI already is an important technology in the mental health sector. With this partnership, we aim to think about new ways to put AI to use for people living with these health disorders. We are proud to welcome iMediSync in the Mila community. ” said Stéphane Létourneau, Executive Vice-President of Mila.

About iMediSync 

iMediSync is the innovative digital mental health platform company integrating FDA-cleared portable electroencephalogram (EEG) brain scanner with NIR-LED photobiomodulation and cloud-based quantitative electroencephalogram (QEEG) automatic analysis system targeting early detection and preventive care for dementia, Alzheimer’s disease, mood problems, and other mental disorders, even at the preclinical stage. It’s revolutionizing diagnostics and enhancing the accessibility to mental healthcare by digitizing conventional EEG with AI technology. iMediSync has successfully developed an AI/ML algorithm for detecting mild cognitive impairment or Alzheimer’s disease. iMediSync has partnered with over 25 hospitals and medical centers to improve mental health analysis and care especially after the effects of a pandemic.

About Mila

Founded by Professor Yoshua Bengio of the University of Montreal, Mila is an artificial intelligence research institute that brings together over 1,000 researchers specializing in machine learning. Based in Montreal, Mila’s mission is to be a global hub for scientific advances that inspire innovation and development of AI for the benefit of all. Mila is a non-profit organization recognized worldwide for its significant contributions to the field of deep learning, particularly in language modeling, machine translation, object recognition, and generative models.